Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.


Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
08 03 2022
Historique:
received: 10 08 2021
revised: 17 11 2021
accepted: 21 01 2022
pubmed: 14 2 2022
medline: 15 3 2022
entrez: 13 2 2022
Statut: ppublish

Résumé

Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for many months. We delineated the immune-proteomic landscape in the airways and peripheral blood of healthy controls and post-COVID-19 patients 3 to 6 months after hospital discharge. Post-COVID-19 patients showed abnormal airway (but not plasma) proteomes, with an elevated concentration of proteins associated with apoptosis, tissue repair, and epithelial injury versus healthy individuals. Increased numbers of cytotoxic lymphocytes were observed in individuals with greater airway dysfunction, while increased B cell numbers and altered monocyte subsets were associated with more widespread lung abnormalities. A one-year follow-up of some post-COVID-19 patients indicated that these abnormalities resolved over time. In summary, COVID-19 causes a prolonged change to the airway immune landscape in those with persistent lung disease, with evidence of cell death and tissue repair linked to the ongoing activation of cytotoxic T cells.

Identifiants

pubmed: 35151371
pii: S1074-7613(22)00046-2
doi: 10.1016/j.immuni.2022.01.017
pmc: PMC8789571
pii:
doi:

Substances chimiques

Immunoproteins 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

542-556.e5

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S004068/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V027638/1
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

J Leukoc Biol. 2014 Feb;95(2):215-24
pubmed: 24006506
Nature. 2021 Jul;595(7866):283-288
pubmed: 34010947
Thorax. 2021 Oct;76(10):1010-1019
pubmed: 33846275
Ann Am Thorac Soc. 2021 May;18(5):799-806
pubmed: 33433263
Am J Respir Crit Care Med. 2019 Jul 15;200(2):209-219
pubmed: 31051082
BMJ Open Respir Res. 2020 Sep;7(1):
pubmed: 32963028
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
Immunity. 2021 Apr 13;54(4):617-631
pubmed: 33852829
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
J Exp Med. 2010 Jun 7;207(6):1161-72
pubmed: 20513748
J Virol. 2008 May;82(9):4441-8
pubmed: 18287232
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
J Exp Med. 2020 Mar 2;217(3):
pubmed: 31917836
Nat Commun. 2021 May 21;12(1):3010
pubmed: 34021148
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Cell Rep Med. 2021 May 18;2(5):100287
pubmed: 33969320
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
J Exp Med. 2017 Aug 7;214(8):2387-2404
pubmed: 28694385
Immunity. 2021 Apr 13;54(4):797-814.e6
pubmed: 33765436
Sci Immunol. 2021 Nov 12;6(65):eabk1741
pubmed: 34591653
Nature. 2020 Nov;587(7834):466-471
pubmed: 33116313
Lancet. 2021 Jul 17;398(10296):223-237
pubmed: 34274064
Radiology. 2021 Oct 5;:211746
pubmed: 34609195
Am J Respir Crit Care Med. 2021 Feb 1;203(3):339-347
pubmed: 32692582
Front Immunol. 2018 Apr 09;9:678
pubmed: 29686673
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Front Med (Lausanne). 2018 Mar 20;5:43
pubmed: 29616220
Immunity. 2013 Nov 14;39(5):939-48
pubmed: 24238342
Radiology. 2021 Apr;299(1):E177-E186
pubmed: 33497317
Am J Pathol. 2011 Oct;179(4):1733-45
pubmed: 21871427
Sci Immunol. 2017 Jan 6;2(7):
pubmed: 28783666
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
Am J Physiol Lung Cell Mol Physiol. 2016 Oct 1;311(4):L687-L695
pubmed: 27542809
Stat Appl Genet Mol Biol. 2005;4:Article17
pubmed: 16646834
Immunity. 2021 Feb 9;54(2):259-275.e7
pubmed: 33382972
Elife. 2021 Mar 11;10:
pubmed: 33704068
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Respir Res. 2019 Nov 6;20(1):244
pubmed: 31694639
iScience. 2020 Jun 26;23(6):101160
pubmed: 32405622
Sci Immunol. 2019 Apr 5;4(34):
pubmed: 30952804
Sci Immunol. 2021 Nov 19;6(65):eabl9105
pubmed: 34618554
Front Immunol. 2016 Feb 05;7:25
pubmed: 26904022
Immunity. 2018 Jul 17;49(1):134-150.e6
pubmed: 29958800
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Am J Respir Cell Mol Biol. 2021 Jun;64(6):722-733
pubmed: 33689587

Auteurs

Bavithra Vijayakumar (B)

National Heart and Lung Institute, Imperial College London, London, UK; Chelsea and Westminster Hospital, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Karim Boustani (K)

National Heart and Lung Institute, Imperial College London, London, UK; Asthma UK Centre for Allergic Mechanisms of Asthma, London, London, UK.

Patricia P Ogger (PP)

National Heart and Lung Institute, Imperial College London, London, UK.

Artemis Papadaki (A)

Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.

James Tonkin (J)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Christopher M Orton (CM)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Poonam Ghai (P)

National Heart and Lung Institute, Imperial College London, London, UK.

Kornelija Suveizdyte (K)

National Heart and Lung Institute, Imperial College London, London, UK.

Richard J Hewitt (RJ)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Sujal R Desai (SR)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK; Margaret Turner-Warwick Centre for Fibrosing Lung Diseases, London, UK.

Anand Devaraj (A)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Robert J Snelgrove (RJ)

National Heart and Lung Institute, Imperial College London, London, UK; Asthma UK Centre for Allergic Mechanisms of Asthma, London, London, UK.

Philip L Molyneaux (PL)

National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Justin L Garner (JL)

Chelsea and Westminster Hospital, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

James E Peters (JE)

Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.

Pallav L Shah (PL)

National Heart and Lung Institute, Imperial College London, London, UK; Chelsea and Westminster Hospital, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Clare M Lloyd (CM)

National Heart and Lung Institute, Imperial College London, London, UK; Asthma UK Centre for Allergic Mechanisms of Asthma, London, London, UK.

James A Harker (JA)

National Heart and Lung Institute, Imperial College London, London, UK; Asthma UK Centre for Allergic Mechanisms of Asthma, London, London, UK. Electronic address: j.harker@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH